NASDAQ:IART Integra LifeSciences (IART) Stock Price, News & Analysis $13.33 -0.12 (-0.89%) Closing price 04:00 PM EasternExtended Trading$13.20 -0.14 (-1.01%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Integra LifeSciences Stock (NASDAQ:IART) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Integra LifeSciences alerts:Sign Up Key Stats Today's Range$13.27▼$13.7650-Day Range$12.68▼$18.3452-Week Range$8.70▼$20.49Volume1.31 million shsAverage Volume907,235 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$16.71Consensus RatingReduce Company Overview Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs. The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery. Integra is also known for its artificial-skin and dermal regeneration products, which are used to support the treatment of burns and other serious wounds. Founded in 1989, Integra serves hospitals, surgical centers, and healthcare professionals in the United States and international markets. Its business is organized around technologies and products for neurosurgery and reconstructive and orthopedic surgery, with a focus on improving patient outcomes and supporting tissue repair.AI Generated. May Contain Errors. Read More Integra LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreIART MarketRank™: 3.52503652543 of 5 starsIntegra LifeSciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 140th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingReduce Consensus RatingIntegra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, 1 buy rating, 5 hold ratings, and 2 sell ratings.Upside PotentialIntegra LifeSciences has a consensus price target of $16.71, representing about 25.4% upside from its current price of $13.33.Amount of Analyst CoverageIntegra LifeSciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Integra LifeSciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth3.35% Earnings GrowthEarnings for Integra LifeSciences are expected to grow by 3.35% in the coming year, from $2.39 to $2.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Integra LifeSciences is -148.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Integra LifeSciences is -148.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioIntegra LifeSciences has a PEG Ratio of 0.70. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioIntegra LifeSciences has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Integra LifeSciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.72% of the float of Integra LifeSciences has been sold short.Short Interest Ratio / Days to CoverIntegra LifeSciences has a short interest ratio ("days to cover") of 7.51.Change versus previous monthShort interest in Integra LifeSciences has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntegra LifeSciences does not currently pay a dividend.Dividend GrowthIntegra LifeSciences does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.13 News SentimentIntegra LifeSciences has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Integra LifeSciences this week, compared to 4 articles on an average week.MarketBeat Follows3 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Integra LifeSciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.84% of the stock of Integra LifeSciences is held by insiders.Percentage Held by Institutions84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Integra LifeSciences' insider trading history. Receive IART Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IART Stock News HeadlinesIntegra LifeSciences Holdings Closes $450 Million Senior Secured Notes OfferingOctober 20 at 9:55 AM | finance.yahoo.comIntegra Announces Completion of Refinancing TransactionsOctober 19 at 4:05 PM | globenewswire.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 20 at 1:00 AM | Behind the Markets (Ad)Integra LifeSciences Holdings Corporation (NASDAQ:IART) Stock Has Consensus Target Price of $17.29 According to AnalystsOctober 18 at 3:30 AM | americanbankingnews.comIntegra LifeSciences to Showcase ENT Portfolio and Support New Clinical Research at AAO-HNSF Annual MeetingOctober 16, 2026 | quiverquant.comQIntegra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual MeetingOctober 16, 2026 | globenewswire.comIntegra LifeSciences (NASDAQ:IART) Stock Price Target Cut by Truist FinancialOctober 16, 2026 | americanbankingnews.comTruist Securities Adjusts Integra LifeSciences Price Target to $15 From $19October 14, 2026 | finance.yahoo.comSee More Headlines IART Stock Analysis - Frequently Asked Questions How have IART shares performed this year? Integra LifeSciences' stock was trading at $12.42 on January 1st, 2026. Since then, IART stock has increased by 7.3% and is now trading at $13.33. How were Integra LifeSciences' earnings last quarter? Integra LifeSciences Holdings Corporation (NASDAQ:IART) announced its earnings results on Wednesday, July, 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. The life sciences company earned $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a positive trailing twelve-month return on equity of 18.30% and a negative net margin of 0.44%. Read the conference call transcript. When did Integra LifeSciences' stock split? Shares of Integra LifeSciences split on the morning of Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Integra LifeSciences have any subsidiaries? Integra LifeSciences subsidiaries include ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and others. Who are Integra LifeSciences' major shareholders? Integra LifeSciences' top institutional shareholders include State of Alaska Department of Revenue (0.02%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen and Jeffrey A Graves. View institutional ownership trends. How do I buy shares of Integra LifeSciences? Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Integra LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Gilead Sciences (GILD), Micron Technology (MU), Eli Lilly and Company (LLY), Block (XYZ), Adobe (ADBE), Medtronic (MDT) and Boeing (BA). Company Calendar Last Earnings7/29/2026Today10/20/2026Next Earnings (Estimated)10/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, IART's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:IART CIK917520 Webwww.integralife.com Phone(609) 275-0500Fax609-750-4277Employees4,427Year Founded1989Price Target and Rating Average Price Target for Integra LifeSciences$16.71 High Price Target$25.00 Low Price Target$13.00 Potential Upside/Downside+25.4%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E Ratio5.58 P/E Growth0.7Net Income-$516.47 million Net Margins-0.44% Pretax Margin-0.01% Return on Equity18.30% Return on Assets5.30% Debt Debt-to-Equity Ratio1.75 Current Ratio3.60 Quick Ratio2.11 Sales & Book Value Annual Sales$1.64 billion Price / Sales0.63 Cash Flow$4.26 per share Price / Cash Flow3.13 Book Value$13.40 per share Price / Book0.99Miscellaneous Outstanding Shares77,770,000Free Float74,787,000Market Cap$1.04 billion OptionableOptionable Beta1.21 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IART) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Integra LifeSciences Holdings Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Integra LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
